ArticleJournal of neuro-oncology2025
Prognostic factors and quality of life in non-small cell lung cancer with leptomeningeal metastasis: a dichotomous pattern based on parenchymal involvement.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study retrospectively analyzed prognostic factors and quality of life in patients with Non-Small Cell Lung Cancer–Leptomeningeal Metastasis (NSCLC-LM), stratified by the presence or absence of concomitant Parenchymal Metastasis (PM), to inform clinical stratification and individualized therapy.
methodsWe retrospectively reviewed 43 NSCLC-LM patients diagnosed at the Affiliated People’s Hospital of Jiangsu University from September 2016 to April 2025, and classified them into LM-PM and LM-noPM groups according to brain parenchymal metastasis status. The primary endpoint was median overall survival (mOS). Prognostic factors were assessed, and quality of life was evaluated before and after treatment. Survival analysis was performed using the Kaplan-Meier method and log-rank test. Univariate and multivariate Cox regression analyses were conducted to identify independent prognostic factors. Quality of life scores were compared using paired sample t-tests. Scale reliability was assessed via Pearson correlation coefficients and Cronbach’s alpha. Statistical significance was defined as a two-sided P-value < 0.05.
resultsThe mOS was 5.0 months in both groups. Notably, the LM-noPM group demonstrated higher 1-year and 2-year survival rates, indicating a possible long-term survival advantage, although this trend did not reach statistical significance. Multivariate analysis identified non-receipt of anti-angiogenic therapy, adrenal metastasis, and elevated Platelet–Lymphocyte Ratio (PLR) as independent risk factors for poor prognosis. Among patients with good performance status, meningeal irritation signs also constituted an independent risk factor. Quality of life assessment revealed that comprehensive treatment significantly improved global health status and functional domains while reducing symptom burden.
conclusionAlthough NSCLC-LM patients without PM showed a non-significant trend toward improved long-term survival (reflected by numerically higher 1- and 2-year survival rates), the key independent risk factors associated with poor prognosis were the absence of anti-angiogenic therapy after LM diagnosis, the presence of adrenal metastasis, and an elevated PLR. These findings remained consistent among patients with good performance status, among whom meningeal irritation signs also independently predicted worse outcomes. Moreover, comprehensive treatment significantly alleviated symptom burden and enhanced quality of life across multiple domains, supporting longer survival with improved quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.